Beat The Denominator

Consider Hims & Hers Health (HIMS) as a long-term investment, with its upcoming Q3 earnings report serving as a key short-term catalyst. The stock is considered an attractive buy in the $4.00 - $4.50 price range due to its high volatility. Key growth drivers to watch for include the new microdose GLP-1 offering and the recently launched testosterone treatment line. The 'Hers' brand's new menopause treatments are expected to be a significant long-term growth engine, potentially becoming a billion-dollar business. In the upcoming earnings report, investors should focus on revenue stabilization after the Novo Nordisk partnership ended.

MicroStrategy's (MSTR) management is signaling a strong belief that Bitcoin will reach new highs by the end of the year, making MSTR a high-conviction play on this outlook. The company reassured investors that it only sells its stock "into strength," reducing concerns about dilution during downturns. For those seeking lower risk, the company is heavily promoting its "Stretch" preferred stock (STRC), a low-volatility and short-duration instrument. STRC is viewed internally as a "killer app" and a major future growth driver for the company. Investors should watch for the price of STRC to approach the key $100 level as a potential catalyst.

Analysts maintain an average price target of $587 on MSTR, viewing the company as a stable, long-term investment following its recent earnings report. These same analysts project Bitcoin (BTC) could reach $156,000, suggesting the current price may be a buying opportunity despite recent volatility. For income investors, consider the preferred instrument Stretch (STRC), which offers a tax-adjusted yield of 16% and is set for a yield increase to push its price toward $100. A similar instrument, Strike, provides an even higher tax-adjusted yield of 21%. The dividends from both instruments are structured as a tax-free return of capital for roughly the first 10 years, making them highly attractive for long-term compounding.

Consider owning MicroStrategy (MSTR) common stock ahead of its Q3 earnings call, which is expected to announce a significant catalyst like a stock buyback or a new yield strategy on its Bitcoin holdings. The current price drop in Solana (SOL) is presented as a buying opportunity for long-term investors, offering an attractive native staking yield of around 8%. For a discounted entry into Solana, look into treasury company UPEXI, which trades at a 32% discount to the value of the Solana it holds. Alternatively, DeFi DV offers a 16% discount to its Solana holdings while earning a 10% staking yield. Despite current market fear, the long-term conviction remains very bullish on these assets, viewing this period as a temporary buying opportunity.

Consider the recent price drop in TransMedics (TMDX) as a potential buying opportunity, as the market appears to be overreacting to a predictable seasonal slowdown. The company is performing strongly, having raised its full-year revenue guidance with analysts modeling 44% growth over the next year. Conversely, Enphase Energy (ENPH) faces significant headwinds from high interest rates and a clear competitive threat from Tesla (TSLA). With analysts predicting a 16% sales decline next year, the stock appears expensive even after its significant price fall. Therefore, investors should be cautious with ENPH as its core growth has stalled.

The Federal Reserve's policy of cutting rates and ending Quantitative Tightening by December 1st is creating a major tailwind for risk-on assets. This environment is expected to push capital from money market funds into assets like Bitcoin, which is viewed as a primary beneficiary of this capital rotation. NVIDIA (NVDA) remains a top conviction idea, with management targeting a stunning $500 billion in sales over the next five quarters. A related high-conviction trade is an instrument called "stretch," which is expected to be mechanistically forced to a price of $100 due to the new interest rate environment. For a more stable growth play, Google (GOOGL) is attractive as its revenue diversifies beyond search and the market begins to recognize the value of its Cloud and YouTube segments.

For exposure to Solana, Upexi (UPXI) is presented as the best value opportunity, allowing you to buy the asset at a 31% discount while earning an 8-10% staking yield. Similarly, Sharplink Gaming (SBET) offers a clear arbitrage play to acquire Ethereum at a 17% discount to its market price. For leveraged Bitcoin exposure, MicroStrategy (MSTR) is considered a compelling value, with some technical traders targeting a move to $500 - $520 within 3 to 6 months. These digital asset treasury companies are trading at significant discounts to the crypto they hold, creating a clear value opportunity. The core strategy is to use these stocks as a vehicle to acquire major crypto assets for cheaper than their direct market price.

Consider buying Oddity Tech (ODD) on any weakness ahead of its major new brand launch, which is expected in the second half of 2024. For real estate exposure, Realty ONE Group (REAX) is presented as a clear buy and a top pick due to its attractive valuation. In the insurtech sector, Root Insurance (ROOT) is highlighted as a favorite high-growth play that appears very cheap relative to its rapid expansion. Keep an eye on premium footwear brand On Holdings (ONON), which is viewed as an undervalued 'Nike challenger' that could present a buying opportunity for long-term investors. Lastly, Gambling.com (GAMB) offers a potentially cheap way to invest in the growing US online gambling market.

MicroStrategy (MSTR) is presented as a compelling long-term investment, as its recent stock underperformance relative to Bitcoin may signal a buying opportunity. The company's new B+ credit rating from S&P is viewed as a major positive catalyst that could attract institutional investors over time, despite its "junk" status. Furthermore, MSTR's aggressive strategy of raising capital to continuously acquire more Bitcoin is a core part of its fundamental value proposition. For investors seeking more direct and simple exposure to Bitcoin's price, the iShares Bitcoin Trust (IBIT) offers a straightforward alternative that closely tracks the asset. The overall market sentiment for Bitcoin is improving as its price strengthens and market fear subsides.

Bitcoin (BTC) is showing strong bullish momentum, approaching $114,000, driven by optimism around an imminent US-China trade deal. For higher-risk exposure, consider smaller Bitcoin-holding companies like Strive (ASST), which are rebounding strongly and acting as leading indicators for the sector. MicroStrategy (MSTR) offers a more stable, though potentially lagging, way to gain Bitcoin exposure through the stock market. Separately, watch for a potential catalyst for Nvidia (NVDA) from the upcoming Jensen keynote on Tuesday. The overall market outlook is positive, supported by a likely Fed rate cut and progress on the trade deal.

Consider a short-term bullish position on Bitcoin (BTC) this week, as it could benefit from strong Big Tech earnings, an expected Fed rate cut on Wednesday, and positive China trade deal news. For leveraged exposure to this potential Bitcoin rally, look at MicroStrategy (MSTR), as its stock price is highly correlated to BTC. MSTR's recent stock decline has been more severe than the drop in its underlying asset value, potentially offering a discounted entry point for investors bullish on Bitcoin. Also, monitor the NVIDIA (NVDA) conference on Tuesday, as a positive outlook could lift the NASDAQ and further support Bitcoin. Given the difficulty in timing price jumps, a strategy of staying invested through these key events is suggested to avoid missing potential upside.

Tesla (TSLA) is presented as a top high-risk, high-reward opportunity, with the Robotaxi network expected to begin rolling out by the end of the year. Despite its large market cap, NVIDIA (NVDA) is considered the most attractive and undervalued stock due to its dominant AI chip position and strong fundamentals. Google (GOOGL) is viewed as a safer, discounted investment whose price does not fully reflect the value of assets like YouTube and its stake in SpaceX. Consider Amazon (AMZN) as a "dirt cheap" laggard poised to benefit from its logistics network and potential regulatory changes hurting foreign competitors. Conversely, investors should be cautious with Apple (AAPL) due to its high valuation, low growth forecasts, and a perceived failure to innovate.

Consider "UPEXI" as a way to gain exposure to the Solana blockchain at a nearly 30% discount to its asset value, presenting a significant buying opportunity after its recent price drop. Nebius is an undervalued AI infrastructure play whose new Microsoft partnership is expected to drive over 1600% revenue growth in the next year. For a higher-risk value trade, Oscar Health (OSCR) is considered "dirt cheap" with a potential political catalyst that could send the stock toward $30. As mortgage rates fall, The Real Brokerage (REAX) offers a cheap investment into a real estate market recovery, trading at a price-to-sales ratio of just 0.10. Finally, an investment in MicroStrategy (MSTR) is a leveraged bet on Bitcoin, which is believed to be near a bottom and poised for a rebound by year-end.

MicroStrategy (MSTR) is viewed as an undervalued buying opportunity, supported by recent insider buying and a $485 price target from Citibank. Despite high volatility, Hims & Hers (HIMS) presents a long-term growth play due to its strategic investment in at-home cancer screening. The AI data center sector is experiencing a pullback, creating potential entry points for investors with a long-term view. Consider watching Bitcoin miners pivoting to AI, like Marathon Digital (MARA) near $17-$18 and CleanSpark (CLSK) around $15. Additionally, the pure-play AI cloud company Nubis (NBIS) is considered an interesting buy at its current level near $102.

Consider CoreMedics (CRMD) as a high-conviction opportunity, with the analyst stating it remains "extremely cheap" even after a 17% gain driven by strong revenue and an analyst upgrade. The speaker believes the stock "had no business getting below $10" and has significant growth potential. As a popular proxy for Bitcoin, MicroStrategy (MSTR) is viewed as a bullish investment with a potential future price target above $400. This outlook is supported by Bitcoin (BTC) itself, which is rebounding strongly from a period of 'extreme fear,' suggesting the recent lows may have presented a buying opportunity. Lastly, fintech stock SoFi (SOFI) is showing positive momentum as it appears to be breaking out of its long-term trading range.

With market sentiment at "very high fear" and a potential resolution to US-China trade tensions expected soon, now may be an opportune time to buy into weakness. Consider accumulating Bitcoin (BTC) following its recent recovery from the sub-$103,000 dip, as this could signal a short-term bottom. For investors seeking stock market exposure to crypto, MicroStrategy (MSTR) is presented as a key proxy for Bitcoin. Prominent analyst Tom Lee is "extremely bullish" on MSTR, calling it a high-conviction "granny shot" investment. Investors should watch for a potential "Dodd Day" announcement from the company, which could act as a positive catalyst for the stock.

MicroStrategy (MSTR) is demonstrating significant relative strength, making it a high-conviction investment for those seeking Bitcoin exposure through stocks. The company is currently outperforming both Bitcoin (BTC) itself and related funds like the iShares Bitcoin Trust (IBIT). A key bullish indicator is the rising premium investors are willing to pay for MSTR over its underlying Bitcoin holdings, suggesting strong market confidence. Furthermore, the strong performance of its preferred stock, Strife, gives the company an attractive way to fund future Bitcoin acquisitions. For now, MSTR appears to be the dominant leader for investors looking to gain crypto exposure in the equity market.

The recent 21% drop in Hims & Hers (HIMS) stock is viewed as a buying opportunity based on a market overreaction to GLP-1 drug pricing news. The investment thesis is that HIMS is a diversified telehealth platform, not just a weight-loss company, with strong core businesses in areas like erectile dysfunction and anxiety. Hims' primary value is its bundled, affordable access to doctors, which remains compelling regardless of drug prices. The company is also insulated by its successful, lower-cost weight loss alternatives, including an oral kit starting at $69/month. In contrast, investors should be aware that major GLP-1 producers like Novo Nordisk (NVO) and Eli Lilly (LLY) carry significant political headline risk and volatility.

The analyst is extremely bullish on MicroStrategy's preferred stocks, highlighting one called "stretch" for its attractive and tax-advantaged 10.53% effective yield. DFDV, a proxy for Solana (SOL), is presented as a clear buying opportunity as it trades below its asset value of $14.60 and has an upcoming warrant dividend. A basket of hyper-growth stocks including CorMedix (CRMD), The Real Brokerage (REAX), and Hims & Hers (HIMS) are seen as irrationally sold-off, creating excellent entry points. Specifically, CorMedix (CRMD) is described as "dirt cheap" near $10 a share, with projected revenue growth of 180%. These opportunities exist because the market is in "extreme fear," which is viewed as an ideal time to invest for the long term.